Revenue
2021
2022
Grace Therapeutics, Inc. (GRCE)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
2026
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
2026
Financial statements
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0 | $196,000 | — | — |
| Research & development | $2.4M | $9.5M | $4.7M | $10.0M | $5.6M | $4.2M | $16.0M | $29.4M |
| Operating income | −$11.1M | −$16.7M | −$12.9M | −$52.2M | −$15.6M | −$16.4M | −$24.4M | −$34.4M |
| EBITDAderived | — | — | — | — | −$15.6M | −$15.5M | −$22.1M | −$32.1M |
| Net income | −$7.8M | −$9.6M | −$12.9M | −$42.4M | −$9.8M | −$19.7M | −$25.5M | −$39.4M |
| Basic EPSper diluted share | -$0.47 | -$0.79 | -$1.35 | -$5.71 | -$0.27 | -$1.33 | -$0.30 | -$0.73 |
| Diluted EPSper diluted share | -$0.47 | -$0.79 | -$1.35 | -$5.71 | -$0.27 | -$1.33 | -$0.30 | -$0.73 |